This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
A recent hypothesis1 implicated chronic cerebrospinal venous insufficiency (CCSVI) in the etiology of multiple sclerosis (MS). The postulated mechanism states that iron accumulation in the brains of patients with MS was caused by blockade of the cerebral veins, resulting in reduced blood flow, extravasation of erythrocytes, and iron deposition leading to oxidative tissue damage. This hypothesis left patients in a quandary: Should they pursue diagnosis and amelioration of vein blockade for treatment of MS, and must they avoid iron in order to improve their quality of life?
In this issue of Neurology®, Worthington et al.2 challenge this proposal, reasoning that if parenchymal brain iron deposition were present in MS, it should be reflected by increased CSF ferritin (the iron storage protein). Their study showed that while CSF ferritin levels were pathologically raised in patients with superficial siderosis and subarachnoid hemorrhage, a significantly lower number of patients with MS were affected by high ferritin levels. Furthermore, CSF ferritin did not increase in patients with MS over a …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen
► Watch
Topics Discussed
Alert Me
Recommended articles
Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency
Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome
Progressive multiple sclerosis is not associated with chronic cerebrospinal venous insufficiency
Altered systemic iron metabolism in Parkinson's disease